2024 年第 6 期 第 0 卷

重症肌无力发病和治疗情况概述及抗体类药物应用研究进展

Overview of pathogenesis and treatment of myasthenia gravis and progress of research on the application of antibody drugs

作者：欧瑞阳

英文作者：Ou Ruiyang

单位：四川大学华西医院神经内科，成都610041

英文单位：Department of Neurology West China Hospital Sichuan University Chengdu 610041 China Email: oy18919560953@163.com

关键词：四川省卫生和计划生育委员会科研课题（150161）

英文关键词：Antibodydrugs;Antigen;Myastheniagravis

• 摘要：

• 重症肌无力（MG）是一种获得性自身免疫性疾病，由神经肌肉传递障碍引起的骨骼肌收缩无力为主要症状。MG常见治疗方法包括抗胆碱酯酶药物治疗、皮质激素治疗、免疫抑制剂治疗、血浆置换治疗、手术治疗等，其中MG常用药物选择多样，如糖皮质激素、硫唑嘌呤、免疫抑制剂等，均被证实具有一定疗效。随着医学界对MG疾病机制与药物研究的深入及生物技术的发展，尤其是如新生儿Fc受体靶点抗体类药物、抗补体5抗体类药物、表面抗原-抗体药物等抗体类药物的诞生，给MG用药方案带来更多科学有效的治疗选择。本文就MG发病和治疗情况进行概述、并对抗体类药物在MG治疗中的研究进展展开论述。

• Myasthenia gravis (MG) is an acquired autoimmune disease, the main symptom of which is the weakness of skeletal muscle contraction caused by neuromuscular transmission disorders. Common treatment methods for MG include anticholinesterase drug therapy, corticosteroid therapy, immunosuppressive therapy, plasma exchange therapy, surgical therapy, etc. Among them, there are various drugs commonly used for MG, such as glucocorticoids, azathioprine, immunosuppressants, etc., which have been confirmed to have certain curative effects. With the in-depth research of MG mechanism and drugs in the medical community and the development of biotechnology, especially the birth of antibody drugs such as neonatal Fc receptor target antibody drugs, anti-complement 5 antibody drugs and surface antigen-antibody drugs, drug regimen of MG has brought more scientific and effective treatment options. This paper provides an overview of the incidence and treatment of MG, and reviews the research progress of antibody drugs in MG therapy.